Foreword.Preface.
Acknowledgements.
Chapter 1 Epidemiology of Lipids, Lipid Management and Risk for Coronary Heart Disease: An Overview.
1.1 Early History of Cardiovascular Epidemiology.
1.2 Lipid Risk Factors are Central to Efforts at CHD Prevention.
1.3 LDL-C and CHD Risk.
1.4 LDL-C Lowering and CHD Risk Reduction.
1.5 Other Atherogenic Lipoproteins: Atherogenic Remnants.
1.6 HDL-C and CHD Risk.
1.7 Trends in Lipids and Lipid Management in the USA.
1.8 The National Cholesterol Education Program Evaluation Project Using Novel E-Technology (NEPTUNE) II Survey.
Controversy: Should a Measure of Atherogenic Lipoprotein Particle Number be used in Risk Assessment And/Or to Evaluate the Response to Lipid Therapy?
Chapter 2 Vascular Biology and Atherogenesis.
2.1 Introduction.
2.2 Arterial Structure.
2.3 Endothelial Cell Function and Dysfunction.
2.4 The Role of Monocytes and Lymphocytes.
2.5 Atheromatous Plaques.
Chapter 3 Detection, Evaluation, and Treatment Goals for Lipid Disorders in Adults.
3.1 Matching Aggressiveness of Treatment to Absolute Risk.
3.2 Screening for Dyslipidemias.
3.3 Risk Stratification.
3.4 Steps in the Risk Stratification Process ??? Major Risk Categories.
3.5 Tips for Calculating the Framingham Risk Score.
3.6 Subcategories for Consideration ofMore Aggressive Optional Treatment Goals.
3.7 Very High Risk Patients, Optional LDL-C Goal 70 mg dl/i???1 40.p3.8 iModerately High Risk Patients, OPTIONAL LDL-C Goal 100 mg dl/i???1 40.p3.9 iTreatment Goals for Patients with Elevated Triglycerides./ip3.10 iTriglycerides and HDL-C as Targets for Therapy./ipiControversy: Should Treatment Guidelines Include Targets for the Total/HDL Cholesterol Ratio?/ipChapter 4 bTherapeutic Lifestyle Changes in the Management of Lipid Disorders and the Metabolic Syndrome./bp4.1 iNature and Nurture in the Development of CHD Risk Factors./ip4.2 iLifestyle Factors as Determinants of CHD Risk in Populations./ip4.3 iWithin Country Variations in Lifestyle and CHD Risk./ip4.4 iThe Metabolic Syndrome./ip4.5 iTherapeutic Lifestyle Changes./ip4.6 iThe TLC Diet./ip4.7 iDietary Adjuncts: Viscous Fibers and Plant Sterol/Stanol Products./ip4.8 iPhysical Activity and Weight Reduction./ip4.9 iSmoking Cessation./ip4.10 iImportance of Allied Health Professionals./ipChapter 5 bManagement of Elevated Low-Density Lipoprotein Cholesterol./bp5.1 iRelationship between LDL-C and Risk for Cardiovascular Events./ip5.2 iClinical Trial Support for Very Aggressive LDL-C Reduction for Those at Highest Risk./ip5.3 iGenetic Disorders Associated with Elevated LDL-C./ip5.4 iAtherogenic Impact of LDL-C./ip5.5 iManagement of Elevated LDL-C./ipiControversy: How Low Should We Go?/ipiControversy: Risks and Benefits of High-Dose Statin Therapy Versus Combination Lipid Drug Therapy./ipiControversy: Do the Benefits of Low-Density Lipoprotein Cholesterol Reduction Depend Strictly on ???How Low You Go??? or also on ???How You Get There????/ipChapter 6 bManagement of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol./bp6.1 iClinical Factors Associated with Elevated TG and Non- HDL-C Levels./ip6.2 iDisorders of TG-Rich Lipoprotein Clearance./ip6.3 iInsulin Resistance and Hypertriglyceridemia./ip6.4 iExcessive Production of VLDL: The Primary Lipid Abnormality in the Insulin-Resistant State./ip6.5 iReasons for Elevated Free Fatty Acid Levels in Insulin- Resistant States./ip6.6 iBody Fat Distribution and Insulin Resistance./ip6.7 iInsulin Resistance in the Nonobese Patient./ip6.8 iHypertriglyceridemia and the Development of Atherogenic Dyslipidemia./ip6.9 iLifestyle Management for the Metabolic Syndrome and Atherogenic Dyslipidemia./ip6.10 iDrug Therapies./ip6.11 iIntensification of Efforts to Lower LDL-C as a Means of Achieving the Non-HDL-C Goal./ip6.12 iTargeting Triglyceride-Rich Lipoprotein Reduction as a Means of Achieving Non-HDL-C Goal./ip6.13 iFibrates./ip6.14 iNiacin./ip6.15 iOmega-3 Fatty Acids./ip6.16 iManagement of Diabetic Dyslipidemia./ipiControversy: Do we Need a Triglyceride Treatment Target to Insure a Predominance of Larger, More Buoyant LDLParticles?/ipChapter 7 bManagement of Depressed High-Density Lipoprotein Cholesterol./bp7.1 iThe Relationship between HDL and Risk For CVD./ip7.2 iPrevalence of Low HDL-C./ip7.3 iGoals for HDL Treatment./ip7.4 iAntiatherogenic Effects of HDL./ip7.5 iHDL and Insulin Resistance./ip7.6 iEffects of Lifestyle Modification on Serum HDL./ip7.7 iPharmacologic Management of Low HDL./ipiControversy: Do we Need HDL Treatment Goals?/ipChapter 8 bLipid Management in Population Subsets: Women, the Elderly, Ethnic Minorities, Children, and Adolescents./bp8.1 iWomen./ip8.2 iLipids in Women./ip8.3 iTreatment of Dyslipidemia in Women./ip8.4 iSex Hormone Therapy, Lipids, and Cardiovascular Risk in Menopausal Women./ip8.5 iThe Elderly./ip8.6 iSpecial Considerations for LipidManagement in the Elderly./ip8.7 iEthnic Minorities./ip8.8 iRisk Factor Incidence and Prevalence in Ethnic Minority Groups./ip8.9 iChildren and Adolescents./ipChapter 9 bEmerging Risk Factors and Biomarkers of Cardiovascular Disease./bp9.1 iRole of Inflammation in the Pathogenesis of Atherosclerosis./ip9.2 iBiomarkers of Cardiovascular Disease./ipChapter 10 bA Primer on Clinical Trials and Critical Review of Clinical Trial Reports for the Clinician./bp10.1 iDesign Issues Affecting the Validity and Generalizability of Clinical Trial Results./ip10.2 iChance, Bias, and Confounding as Potential Explanations for Trial Results./ip10.3 iEfficacy versus Effectiveness./ip10.4 iUseful Questions to ask when Evaluating a Published Clinical Trial Report./ippChapter 11 bCase Studies./bbrp
